The quiet symptoms of schizophrenia, and a new kind of treatment.

Symptoms that subtract, not add

Clinicians divide the symptoms of schizophrenia into two families. Positive symptoms are additions: hearing voices, holding beliefs that are not true, thinking in a disorganized way. Negative symptoms are subtractions. Motivation shrinks, so starting and finishing things becomes hard. Pleasure shrinks, both in the moment and in looking forward to anything. Social interest shrinks, so people withdraw from family, friends, and ordinary contact. Speech and expression can flatten as well. Families often notice these changes first, and patients often describe them as laziness or failure. They are neither. They are symptoms of the illness, and the trial paper notes they are strongly linked with poor functioning and quality of life, while no FDA-approved medicine is specifically indicated to treat them.

Why a phone app was tested at all

The techniques with evidence for motivation and pleasure symptoms are psychosocial: setting goals, challenging the defeatist beliefs that say trying is pointless, practicing social skills, building positive experiences back into a week. Delivered in person, that help is time intensive, needs trained clinicians, and is hard for many patients to reach or keep attending. The researchers behind the CONVOKE trial built those techniques into a smartphone program, designed with patient input, and tested whether software could deliver enough of them to matter. The product, CT-155, now cleared under the name Motivista, is prescribed and used alongside regular care. Its FDA clearance, announced October 5, 2026, is as an adjunct to clinician-managed outpatient care including antipsychotic therapy, for adults whose positive symptoms are clinically stable.

How the test was run

CONVOKE was a phase 3, double-blind, randomized trial at 66 sites in the United States, running from March 2023 to June 2025. It enrolled 457 adults with schizophrenia and moderate to severe motivation and pleasure symptoms. Everyone stayed on their antipsychotic medication, at a stable level for at least 12 weeks before joining. By random assignment, 227 people received the therapeutic app and 230 received a control app carrying educational material and daily check-ins. Participants were not told which app was which, and the clinicians rating symptoms did not know either. The study ran 16 weeks, and its main question was whether motivation and pleasure symptoms improved more with the therapeutic app than with the control.

The result, kept to its real size

They did, by a modest margin. On the trial's main scale, symptoms improved 6.8 points with the therapeutic app and 4.2 points with the control app. The 2.6 point gap was statistically significant, and its effect size, 0.36, is described by the authors as small to moderate, in line with effects seen for in-person psychosocial treatment. Engagement was high for a group often described as hard to engage: almost 45 minutes of app use a week, with 70.4 percent of the app group still active through week 15, close to the control group's 76.5 percent. Safety results were quiet. Serious adverse events occurred in 1.3 percent of the app group and 2.2 percent of the control group, and investigators judged none of them related to treatment. The announcement of the clearance calls the gap a 62 percent relative improvement. Both numbers describe the same 2.6 points; the smaller, plainer one is the better guide.

The parts that did not move

A fair summary includes the misses. The improvement was concentrated in social and recreational functioning. The work and school part of the scale barely separated between groups, which the authors note is unsurprising in 16 weeks, since jobs and courses depend on far more than symptoms. Expressive symptoms did not improve significantly, and positive symptoms were unchanged, as expected for a program not designed to treat them. Participants' own overall impression of improvement favored the app at week 8 and was no longer statistically significant at week 16. The trial also leaves out people many readers will know: anyone newly diagnosed, anyone starting or changing antipsychotic treatment, anyone already in psychotherapy, and anyone without a smartphone, regular internet, or stable housing. And the funding deserves naming: Boehringer Ingelheim paid for the study, the two sponsoring companies codeveloped the product, and company employees are among the authors. Independent replication is still owed.

Where therapy and medication each stand

Nothing in this result rearranges the foundations. Antipsychotic medication remains the treatment that controls positive symptoms, and this product is cleared only as an addition to it, for people already stable. What the trial supports is that structured therapeutic work, the goal setting, belief work, and social practice a good therapy hour contains, can move the symptoms medication leaves behind, and that some of that work can be delivered by phone when in-person care is out of reach. It does not show the app replacing a therapist. The trial excluded people receiving psychotherapy, so it cannot compare the two. If negative symptoms are the part of schizophrenia you or someone close to you lives with, the useful step is to describe them concretely in care: what has stopped, what is avoided, what a better month would look like. That description is what lets a clinician judge whether a new adjunct belongs in the plan.

Sources

Everything in this article traces back to the sources below. Figures are the trial's own, from the published paper.

Pratap and colleagues, JAMA Network Open (2026): the CONVOKE trial, a phase 3, double-blind, randomized trial of the smartphone therapeutic CT-155 against a digital control app in 457 adults with negative symptoms of schizophrenia, run at 66 sites in the United States. JAMA Network Open.

ClinicalTrials.gov record NCT05838625: the registered CONVOKE study, its design, its eligibility rules, and its primary outcome measure. ClinicalTrials.gov record.

Click Therapeutics announcement, October 5, 2026: the FDA granted 510(k) clearance to Motivista (CT-155) for the treatment of negative symptoms of schizophrenia, as an adjunct to clinician-managed outpatient care including antipsychotic therapy, in patients 18 years of age and older with clinically stable positive symptoms. FDA clearance announcement.

Please read this part

This article is educational and is not medical advice. It does not create a treatment relationship. The trial described here enrolled a specific group of adults who were stable on medication, and its averages cannot predict any one person's response. Do not start, stop, or change a medicine, or drop therapy, because of anything here. Raise it with your clinician, who can weigh the evidence against your situation.

If you are having thoughts of harming yourself, help is available now: call or text 988, text HOME to 741741 for Crisis Text Line, or call the NAMI Helpline at 1-800-950-6264. This practice is not an emergency service. If someone is in immediate danger, call 911. The crisis page lists more options.